“…The linear relationship between the hydrogel mass loss and the protein release profile confirmed that the erosion of the hydrogel matrix is the key factor for drug release. Such systems that are based on α-cyclodextrin and poly(ethylene glycol) have found wide applications as a drug carriers for low molar mass drugs; nucleic acids; or proteins, such as insulin [88,89], lysozyme [90], human immunoglobulin G [91], antibody-based drugs (such as omalizumab, palivizumab, panitumumab, and ranibizumab [92]), α-chymotrypsin [93], Jack bean urease [94], silver sulfadiazine [95], and siRNA [96]. Recently, systems with nucleobase-terminated PEG were synthesized to improve the rheological properties and prolong drug release.…”